|Print Page Close Window|
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
06/26/18MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
NASDAQ GS | MYOK (Common Stock)
$55.85 + 0.10
07/18/184:02 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.